Bank Of Montreal Allakos Inc. Transaction History

Bank Of Montreal

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2023 Aug 02, 2023	SELL	$3.6 - $5.25 $370,105 - $539,736	-102,807 Reduced 84.4%	19,006 $82,000
Q1 2023 Jun 13, 2024	BUY	$4.3 - $8.27 $81,725 - $157,179	19,006 New	19,006 $84,000
Q4 2022 Feb 01, 2023	BUY	$5.66 - $8.42 $689,461 - $1.03 Million	121,813 New	121,813 $1.03 Million
Q2 2022 Aug 11, 2022	BUY	$2.6 - $6.14 $337,766 - $797,647	129,910 New	129,910 $447,000
Q1 2022 May 12, 2022	SELL	$5.08 - $9.81 $260,253 - $502,576	-51,231 Closed	0 $0
Q4 2021 Feb 11, 2022	BUY	$8.55 - $111.89 $438,025 - $5.73 Million	51,231 New	51,231 $516,000
Q3 2021 Nov 12, 2021	SELL	$76.53 - $110.43 $1.41 Million - $2.03 Million	-18,405 Closed	0 $0
Q2 2021 Aug 12, 2021	BUY	$85.37 - $114.1 $1.57 Million - $2.1 Million	18,405 New	18,405 $1.7 Million

64.7M

47.1K

Ticker ALLK
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 84,726,096
Market Cap $108M
Description
Allakos Inc., a clinical stage biopharmaceutical company, develops therapeutics that target immunomodulatory receptors present on immune effector cells in allergy, inflammatory, and proliferative diseases. The company's lead monoclonal antibody is lirentelimab (AK002), which is in a Phase III study for the treatment of eosinophilic gastritis and...

Get notified when there are updates to the investment portfolio of Bank Of Montreal , based on Form 13F filings with the SEC.

Stay updated on Bank Of Montreal with notifications on news.